Eva Tsalikian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8822499/publications.pdf

Version: 2024-02-01

70 papers	6,626 citations	94433 37 h-index	91884 69 g-index
72 all docs	72 docs citations	72 times ranked	5362 citing authors

#	Article	IF	Citations
1	Diabetes Device Downloading: Benefits and Barriers Among Youth With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2023, 17, 381-389.	2.2	0
2	Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care, 2021, 44, 983-992.	8.6	39
3	Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science Translational Medicine, 2021, 13, .	12.4	142
4	Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 502-514.	11.4	53
5	IL-6 receptor blockade does not slow Î² cell loss in new-onset type 1 diabetes. JCI Insight, 2021, 6, .	5.0	25
6	Altered expression of SIRPÎ³ on the T-cells of relapsing remitting multiple sclerosis and type 1 diabetes patients could potentiate effector responses from T-cells. PLoS ONE, 2020, 15, e0238070.	2.5	5
7	Brain Function Differences in Children With Type 1 Diabetes: A Functional MRI Study of Working Memory. Diabetes, 2020, 69, 1770-1778.	0.6	15
8	Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3265-3278.	3.6	66
9	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 603-613.	27.0	584
10	Executive task-based brain function in children with type 1 diabetes: An observational study. PLoS Medicine, 2019, 16, e1002979.	8.4	15
11	Autoimmunity-associated intronic SNP (rs2281808) detected by a simple phenotypic assay: Unique case or broader opportunity?. Clinical Immunology, 2019, 198, 57-61.	3.2	6
12	Impact of Early Diabetic Ketoacidosis on the Developing Brain. Diabetes Care, 2019, 42, 443-449.	8.6	77
13	Testing the Theory of Resilience and Relational Load (TRRL) in Families with Type I Diabetes. Health Communication, 2019, 34, 1107-1119.	3.1	27
14	Persistence of abnormalities in white matter in children with type 1 diabetes. Diabetologia, 2018, 61, 1538-1547.	6.3	37
15	Individual glucose responses to prolonged moderate intensity aerobic exercise in adolescents with type 1 diabetes: The higher they start, the harder they fall. Pediatric Diabetes, 2018, 20, 99-106.	2.9	42
16	An autoimmune disease risk SNP, rs2281808, in SIRPG is associated with reduced expression of SIRPÎ³ and heightened effector state in human CD8 T-cells. Scientific Reports, 2018, 8, 15440.	3.3	12
17	Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2018, 20, 576-584.	4.4	22
18	Compensatory Hyperconnectivity in Developing Brains of Young Children With Type 1 Diabetes. Diabetes, 2017, 66, 754-762.	0.6	25

#	Article	IF	Citations
19	Stressors in Teens with Type 1 Diabetes and Their Parents: Immediate and Long-Term Implications for Transition to Self-Management. Journal of Pediatric Nursing, 2016, 31, 390-396.	1.5	43
20	Altered Integration of Structural Covariance Networks in Young Children With Type 1 Diabetes. Human Brain Mapping, 2016, 37, 4034-4046.	3.6	23
21	Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult participants in the T1D exchange clinic registry. Pediatric Diabetes, 2016, 17, 327-336.	2.9	177
22	Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes, 2016, 65, 476-485.	0.6	64
23	Cross-Validation of Single-Stage Treadmill Tests for Predicting Aerobic Fitness in Adolescents With Type I Diabetes. Pediatric Exercise Science, 2015, 27, 396-403.	1.0	3
24	Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia. Diabetes, 2015, 64, 1770-1779.	0.6	107
25	Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. Journal of Clinical Investigation, 2015, 125, 3285-3296.	8.2	228
26	Evolution of Abnormal Plasma Glucagon Responses to Mixed-Meal Feedings in Youth With Type 1 Diabetes During the First 2 Years After Diagnosis. Diabetes Care, 2014, 37, 1741-1744.	8.6	38
27	Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatric Diabetes, 2014, 15, 127-134.	2.9	49
28	Skin and Adhesive Issues With Continuous Glucose Monitors. Journal of Diabetes Science and Technology, 2014, 8, 745-751.	2.2	57
29	High success rates of sedation-free brain MRI scanning in young children using simple subject preparation protocols with and without a commercial mock scannerâ€“the Diabetes Research in Children Network (DirecNet) experience. Pediatric Radiology, 2014, 44, 181-186.	2.0	107
30	Neuroanatomical Correlates of Dysglycemia in Young Children With Type 1 Diabetes. Diabetes, 2014, 63, 343-353.	0.6	110
31	Effects of Moderate-to-Vigorous Intensity Physical Activity on Overnight and Next-Day Hypoglycemia in Active Adolescents With Type 1 Diabetes. Diabetes Care, 2014, 37, 1272-1278.	8.6	65
32	Aerobic Fitness and Glycemic Variability in Adolescents with Type 1 Diabetes. Endocrine Practice, 2014, 20, 566-570.	2.1	16
33	Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes and Endocrinology,the, 2013, 1, 284-294.	11.4	169
34	Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes. Diabetes Care, 2013, 36, 1470-1476.	8.6	32
35	Height, BMI, and pituitary volume in individuals with and without isolated cleft lip and/or palate. Pediatric Research, 2012, 71, 612-618.	2.3	13
36	Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual Â-Cell Function. Diabetes Care, 2012, 35, 817-820.	8.6	22

#	Article	IF	Citations
37	Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatric Diabetes, 2012, 13, 301-307.	2.9	78
38	Feeding Frequency and Appetite in Lean and Obese Prepubertal Children. Obesity, 2011, 19, 560-567.	3.0	3
39	Persistence of Individual Variations in Glycated Hemoglobin. Diabetes Care, 2011, 34, 1315-1317.	8.6	61
40	The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care, 2009, 32, 1378-1383.	8.6	347
41	Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 Diabetes. Diabetes Care, 2009, 32, 1954-1959.	8.6	53
42	Normative salivary cortisol values and responsivity in children. Applied Nursing Research, 2009, 22, 54-62.	2.2	45
43	Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator). Pediatric Diabetes, 2008, 9, 142-147.	2.9	94
44	Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal of Medicine, 2008, 359, 1464-1476.	27.0	1,369
45	The Accuracy of the FreeStyle Navigator Continuous Glucose Monitoring System in Children With Type 1 Diabetes. Diabetes Care, 2007, 30, 59-64.	8.6	121
46	Strategies for salivary cortisol collection and analysis in research with children. Applied Nursing Research, 2006, 19, 95-101.	2.2	161
47	Prevention of Hypoglycemia During Exercise in Children With Type 1 Diabetes by Suspending Basal Insulin. Diabetes Care, 2006, 29, 2200-2204.	8.6	194
48	The Effects of Aerobic Exercise on Glucose and Counterregulatory Hormone Concentrations in Children With Type 1 Diabetes. Diabetes Care, 2006, 29, 20-25.	8.6	65
49	Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatric Diabetes, 2005, 6, 13-16.	2.9	121
50	A Randomized Multicenter Trial Comparing the GlucoWatch Biographer With Standard Glucose Monitoring in Children With Type 1 Diabetes. Diabetes Care, 2005, 28, 1101-1106.	8.6	113
51	Function of the GlucoWatchÂ® G2â„¢ Biographer During Exercise. Diabetes Technology and Therapeutics, 2005, 7, 230-230.	4.4	2
52	Impact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes Mellitus. Journal of Pediatrics, 2005, 147, 528-534.	1.8	238
53	GlucoWatch^{Â®}G2â„¢ Biographer Alarm Reliability During Hypoglycemia in Children. Diabetes Technology and Therapeutics, 2004, 6, 559-566.	4.4	33
54	Factors Associated With Academic Achievement in Children With Type 1 Diabetes. Diabetes Care, 2003, 26, 112-117.	8.6	95

#	Article	IF	Citations
55	Effects of Diabetes on Learning in Children. Pediatrics, 2002, 109, e9-e9.	2.1	117
56	ONTOGENY OF THE H19 GENE IN SHEEP AND EFFECT OF MATERNAL FASTING ON ITS EXPRESSION IN THE FETUS. Endocrine Research, 2001, 27, 417-431.	1.2	9
57	Effect of local sympathetic blockade on forearm blood flow and glucose uptake during hypoglycemia. Metabolism: Clinical and Experimental, 1999, 48, 1575-1583.	3.4	9
58	Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening: Journal of the International Society of Neonatal Screening, 1993, 2, 105-139.	0.3	147
59	Augmentation of protein degradation by l-triiodothyronine in uremia. Metabolism: Clinical and Experimental, 1989, 38, 1210-1215.	3.4	33
60	Reduced Renal Clearance of Oxypurinol During a 400 Calorie Proteinâ€Free Diet. Journal of Clinical Pharmacology, 1989, 29, 65-71.	2.0	5
61	Renal clearances of oxypurinol and inulin on an isocaloric, low-protein diet. Clinical Pharmacology and Therapeutics, 1988, 43, 681-687.	4.7	7
62	Sustained reductions in oxipurinol renal clearance during a restricted diet. Clinical Pharmacology and Therapeutics, 1987, 41, 616-621.	4.7	10
63	Mechanism of Hyperglycemia and Response to Treatment with an Inhibitor of Fatty Acid Oxidation in a Patient with Insulin Resistance due to Antiinsulin Receptor Antibodies*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 658-664.	3.6	42
64	Electroencephalographic changes in diabetic ketosis in children with newly and previously diagnosed insulin-dependent diabetes mellitus. Journal of Pediatrics, 1981, 99, 355-359.	1.8	36
65	Glycosylated haemoglobin in children with insulin-dependent diabetes mellitus. Diabetologia, 1980, 19, 423-426.	6.3	20
66	Dopamine during Î±- or Î²-Adrenergic Blockade in Man. Journal of Clinical Investigation, 1979, 63, 310-317.	8.2	45
67	ROLE OF GLUCAGON IN HUMAN DIABETIC KETOACIDOSIS: STUDIES USING SOMATOSTATIN. Clinical Endocrinology, 1976, 5, 299S-305S.	2.4	9
68	The Effect of Somatostatin on Coagulation and Platelet Function in Man. New England Journal of Medicine, 1975, 293, 480-483.	27.0	37
69	Prevention of Human Diabetic Ketoacidosis by Somatostatin. New England Journal of Medicine, 1975, 292, 985-989.	27.0	358
70	PLASMA GLUCAGON AND ALANINE RESPONSES TO ACUTE INSULIN DEFICIENCY IN MAN. Journal of Clinical Endocrinology and Metabolism, 1975, 40, 526-529.	3.6	34